Evidence-Based Medicine Research: This Paper You Will Create

Evidence Based Medicine Researchin This Paper You Will Create Your O

Evidence-Based Medicine: Research In this paper, you will create your own case study about COVID19 and following the SBAR format (situation, background, assessment, and recommendations). Include four (4) different medical-based evidence and/or research recommendations. You must include at least five (5) scholarly sources in your paper. The paper should be 1-3 pages of content in length. Introduction to the case or situation Background detail Clinical assessment Recommendations Application to future practice At least five (5) scholarly references supporting your ideas Follow APA format.

Paper For Above instruction

Introduction

The COVID-19 pandemic has presented unprecedented challenges for healthcare systems worldwide, necessitating rapid adaptation and evidence-based approaches to patient management. This case study applies the SBAR (Situation, Background, Assessment, and Recommendations) framework to a hypothetical COVID-19 patient scenario, integrating current research findings and evidence-based practices to optimize clinical outcomes and inform future healthcare practices.

Situation

A 65-year-old male patient with a history of hypertension and obesity presents to the emergency department with increasing shortness of breath, cough, and fever persisting for three days. His oxygen saturation is 89% on room air, requiring supplemental oxygen. The patient exhibits signs of respiratory distress, including tachypnea and use of accessory muscles. Rapid COVID-19 testing is positive.

Background

The patient’s medical history reveals comorbidities such as hypertension and obesity, which are known to increase the risk of severe COVID-19 illness (Clift et al., 2020). The current pandemic has emphasized the importance of early identification and management of high-risk patients to reduce mortality. Recent studies highlight the evolving treatments, including antiviral drugs, corticosteroids, and monoclonal antibodies, which have shown varying degrees of success in clinical trials (RECOVERY Collaborative Group, 2020; Beigel et al., 2020). Additionally, vaccination remains a critical preventive measure, with studies indicating significant reduction in severe disease and hospitalization rates (Daly et al., 2021). Factors such as age, comorbidities, and timely intervention influence prognostic outcomes (Kang et al., 2021).

Assessment

Clinical examination confirms tachypnea, decreased oxygen saturation, and bilateral infiltrates on chest radiography consistent with COVID-19 pneumonia. Laboratory findings include elevated inflammatory markers like CRP and D-dimer, indicating an ongoing inflammatory response and risk for thromboembolic events (Zhou et al., 2020). Current evidence suggests the importance of early use of corticosteroids, such as dexamethasone, which has been demonstrated to reduce mortality in critically ill COVID-19 patients (RECOVERY Collaborative Group, 2020). Antiviral therapy with remdesivir has shown benefits in shortening recovery time, though its impact on mortality remains debated (Beigel et al., 2020). The use of anticoagulation therapy is recommended due to the high risk of thrombotic complications, supported by recent research (Thachil et al., 2020). Monitoring respiratory status with frequent oxygenation assessments is critical to guide escalation of care.

Recommendations

  • Administer dexamethasone to reduce inflammation and improve survival rates in severe COVID-19 cases, following current clinical guidelines (RECOVERY Collaborative Group, 2020).
  • Initiate antiviral therapy with remdesivir within the first ten days of symptom onset to potentially shorten recovery duration, based on recent evidence (Beigel et al., 2020).
  • Implement prophylactic anticoagulation to mitigate thrombotic risks associated with COVID-19, with dosing adjusted according to patient risk factors (Thachil et al., 2020).
  • Provide supportive oxygen therapy and consider escalation to high-flow nasal cannula or mechanical ventilation for worsening respiratory failure, guided by continuous monitoring (Kang et al., 2021).

Application to Future Practice

This case underscores the importance of an evidence-based, multidisciplinary approach to managing COVID-19. Incorporating current research findings into clinical protocols can improve patient outcomes, especially for high-risk populations. Future practice should focus on early identification of severe cases, timely initiation of therapies like corticosteroids and antivirals, and proactive anticoagulation management. Continuous integration of emerging evidence, particularly regarding novel treatments and vaccination strategies, remains essential to adapt to the evolving pandemic landscape (Daly et al., 2021). Training healthcare providers to stay current with the latest guidelines will enhance patient safety and care quality.

References

  • Beigel, J. H., Tomashek, K. M., Dodd, L. E., et al. (2020). Remdesivir for the treatment of COVID-19 — final report. New England Journal of Medicine, 383(19), 1813–1826.
  • Clift, A. K., Cohen, J., Webster, H. R., et al. (2020). UK Coronavirus Cancer Monitoring Project. COVID-19 mortality and risk factors in patients with cancer. Annals of Oncology, 31(10), 1284–1291.
  • Daly, J., et al. (2021). Effectiveness of mRNA COVID-19 vaccines against variants of concern. Journal of Infectious Diseases, 224(3), 519–529.
  • Kang, S., et al. (2021). Clinical features and management of severe COVID-19. Journal of Clinical Medicine, 10(4), 742.
  • RECOVERY Collaborative Group. (2020). Dexamethasone in hospitalized patients with COVID-19. New England Journal of Medicine, 384(8), 693–704.
  • Thachil, J., et al. (2020). ISTH interim guidance on recognition and management of coagulopathy in COVID-19. Journal of Thrombosis and Haemostasis, 18(5), 1023–1026.
  • Wuhan Zhou, et al. (2020). Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet, 395(10229), 1054-1062.

Related Assignments